Stock 688513 CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Chengdu Easton Biopharmaceuticals Co., Ltd.

Equities

688513

CNE100004397

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-06-27 EDT 		5-day change 1st Jan Change
50.29 CNY -0.34% Intraday chart for Chengdu Easton Biopharmaceuticals Co., Ltd. -7.16% -21.15%
05-22 China Gives Green Light for Easton Biopharma's Arterial Occlusive Disease Tablets MT
04-22 Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. Stock Chengdu Easton Biopharmaceuticals Co., Ltd.
-21.15% 824M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.05% 641B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
B+
NOVARTIS AG Stock Novartis AG
+13.31% 218B
B-
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 159B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
-
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. 688513 Stock
  4. Ratings Chengdu Easton Biopharmaceuticals Co., Ltd.